Blocking the interaction between PD-1 on immune effector cells and PD-L1 on tumor cells has been demonstrated to reverse the suppression of antitumor immunity and has revealed significant antitumor effects in different malignancies, including advanced colorectal cancer (CRC) (17). Here, PDCD1 is linked to colorectal cancer.